Physician profile
Jay W Grosse
NPI 1356568471
$9,340.94
in general payments reported to CMS, 2019-2025
20 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,061 · 2020: $539 · 2021: $1,436 · 2022: $1,238 · 2023: $1,271 · 2024: $1,403 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,825 · Travel and Lodging: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,825.40 |
| Travel and Lodging | $241.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,402.92 | 2019-2025 | |
| Amgen INC. | $1,215.26 | 2019-2024 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $998.10 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $918.94 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $835.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $834.89 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $539.79 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $470.58 | 2022-2025 | |
| Abbvie INC. | $426.54 | 2021-2024 | |
| Novo Nordisk INC | $411.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Allergan, INC. | $266.94 | 2019-2020 | |
| Medtronic, INC. | $241.15 | 2025 | |
| Sanofi-Aventis U.S. LLC | $198.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $193.97 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.90 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $142.01 | 2019 | |
| Xeris Pharmaceuticals, INC. | $40.13 | 2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $24.64 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $19.03 | 2024 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $13.25 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Grosse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.